Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Income from Continuing Operations (2016)

Historic Income from Continuing Operations for Tenax Therapeutics (TENX) over the last 6 years, with Q4 2016 value amounting to -$34.3 million.

  • Tenax Therapeutics' Income from Continuing Operations fell 18307.41% to -$34.3 million in Q4 2016 from the same period last year, while for Dec 2016 it was -$55.5 million, marking a year-over-year increase of 5858.27%. This contributed to the annual value of -$17.6 million for FY2024, which is 12643.43% down from last year.
  • Latest data reveals that Tenax Therapeutics reported Income from Continuing Operations of -$34.3 million as of Q4 2016, which was down 18307.41% from -$4.5 million recorded in Q3 2016.
  • Over the past 5 years, Tenax Therapeutics' Income from Continuing Operations peaked at $108.6 million during Q2 2012, and registered a low of -$118.0 million during Q2 2013.
  • Its 4-year average for Income from Continuing Operations is -$8.0 million, with a median of -$4.6 million in 2016.
  • Over the last 5 years, Tenax Therapeutics' Income from Continuing Operations had its largest YoY gain of 371057.81% in 2012, and its largest YoY loss of 35790.41% in 2012.
  • Over the past 4 years, Tenax Therapeutics' Income from Continuing Operations (Quarter) stood at -$1.6 million in 2012, then plummeted by 7512.64% to -$118.0 million in 2013, then skyrocketed by 89.74% to -$12.1 million in 2015, then tumbled by 183.07% to -$34.3 million in 2016.
  • Its Income from Continuing Operations stands at -$34.3 million for Q4 2016, versus -$4.5 million for Q3 2016 and -$4.7 million for Q2 2016.